This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Advancing the Treatment and Coordination of Care for Huntington's Disease

Advancing the Treatment and Coordination of Care for Huntington's Disease

Format

Webcast

Time to Complete

30 minutes

Released

June 30, 2016

Expires

June 30, 2017
Add to Queue


Maximum Credits

0.50 / AMA PRA Category 1 Credit(s)TM
0.50 / CNE for Nurses
0.50 / CE for Pharmacists (0.05 CEUs)

Accredited Provider



This activity is provided by North American Center for Continuing Medical Education, LLC, an HMP Communications Holdings Company.

Commercial Supporter

This activity is supported by an educational grant from Teva Pharmaceuticals.

Educational Partners

Developed through a collaboration between the American Neurological Association and the Huntington’s Disease Society of America

Program Description

This activity will discuss strategies to aid in early diagnosis of Huntington’s disease (HD), currently available and emerging treatment options and the benefit of multidisciplinary care. HD is a rare, hereditary, severely disabling, and progressive disease with devastating consequences not only to patients, but also to family and caregivers. HD is characterized by a triad of cognitive, behavioral, and motor symptoms that vary across patients, disease stage, in presentation, and seldom occur in isolation—making management challenging and requiring care across multiple specialties.

Fee Information

There is no fee associated with this activity.

Intended Audience

This activity is designed for neurologists, psychiatrists, geriatricians, pharmacists, long-term care professionals, and related healthcare professions who provide care to patients with HD.

Educational Objectives

After completing this activity, participants should be able to:

  • Apply knowledge of the genetic and pathophysiologic basis of HD to strategies that aid in early diagnosis
  • Correlate behavioral, cognitive, and motor symptoms of HD to disease progression, physical and psychosocial functioning, and quality of life
  • Outline the efficacy, safety, and pharmacokinetics/pharmacodynamics of current and emerging HD therapies and the impact of deuteration on treatment
  • Employ a multidisciplinary approach to HD care across practice settings and throughout the disease progression

Conflict Of Interest Disclosure Policy

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Faculty

Kevin M. Biglan, MD, MPH
Professor of Neurology and the Center for Human Experimental Therapeutics
University of Rochester
Rochester, New York
Director, HDSA Center of Excellence at the University of Rochester
Rochester, NY

Dr. Biglan discloses:
Grant/Research Support: Huntington’s Disease Society of America (HDSA), Teva Branded Pharmaceutical Product
Consultant: Teva Branded Pharmaceuticals Product

Samuel A. Frank, MD
Associate Professor of Neurology
Beth Israel Deaconess Medical Center, Harvard Medical School
Boston, Massachusetts
Director, HDSA Center of Excellence at Beth Israel Deaconess Medical Center
Boston, MA

Dr. Frank discloses:
Grant/Research Support: Teva
Board Member: HDSA

Christopher A. Ross, MD, PhD
Professor of Psychiatry, Neurology, Neuroscience and Pharmacology
Johns Hopkins Medicine
Baltimore, Maryland
Director, HDSA Center of Excellence at Johns Hopkins
Baltimore, MD

Dr. Ross discloses:
Grant/Research Support: Teva, Raptor
Consultant: Teva, Raptor, GLG

Independent Clinical Reviewer
Fredy J. Revilla, MD

Professor, University of South Carolina School of Medicine
Chief of the Division of Neurology, Greenville Health System
Greenville, SC

Dr. Revilla has disclosed no relevant financial relationships with any commercial interests.

Nurse Planner
Susie Seaman, NP

Sharp Rees-Stealy Wound Clinic
San Diego, CA

Ms. Seaman discloses the following financial relationships:
Scientific Advisor: Smith & Nephew, Inc.
Promotional Speakers’ Bureau: Smith & Nephew, Inc.

Accredited Provider Disclosure

Donna Brophy, Jennifer Browne, Celeste Collazo, MD, Mary Johnson, Mike Kearney, Randy Robbin, and John Savage, NACCME, have disclosed no relevant financial relationships with any commercial interests.

Planning Committee

The planning committee is comprised of Kevin M Biglan, MD, MPH, Samuel A. Frank, MD, Christopher A. Ross, MD, PhD, Fredy J. Revilla, MD , Susie Seaman, NP. Donna Brophy, Jennifer Browne, Celeste Collazo, MD, Mary Johnson, Mike Kearney, Randy Robbin, and John Savage, NACCME.

Credit

0.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation Statement

NACCME designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

0.50

Type

CE for Nurses

Accreditation Statement

North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation Statement

This continuing nursing education activity awards 0.50 contact hour.

Credit

0.50

Type

CE for Pharmacists

Accreditation Statement

North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation Statement

This activity is approved for 0.50 contact hour (0.05 CEU) of continuing pharmacy education (UAN 0276-0000-16-083-H01-P).

This educational activity is a knowledge-based activity.

ACPE Policies

ACPE Credit Policy
Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

ACPE Grievance Policy
Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Senior Manager, Accreditation and Compliance, NACCME, in writing at 104 Windsor Center Drive, Suite 200, East Windsor, NJ 08520. The Senior Manager, Accreditation and Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Disclosure of Unlabeled Use

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty members have disclosed that this activity may discuss off-label, investigational, use of medications for Huntington’s Disease.

Disclaimer

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.Copyright © 2016 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact Jennifer Browne, jbrowne@naccme.com.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue